Numerous investigators make tremendous and respectable efforts so that well-designed and -executed prospective, double-blind, randomized, controlled trials can determine definitively whether therapies of interest are indeed safe and effective. In this issue of Neurology®, Schoenen et al.1 report the results of such a trial conducted at 5 tertiary headache centers in Belgium. They determined whether migraine attacks can be prevented by trigeminal neurostimulation with a supraorbital transcutaneous stimulator: Cefaly. This stimulation device is fashionably designed and its frame resembles a lightweight tiara or sporty sunglasses.
No comments:
Post a Comment